VISCHER assisted ProteoMedix AG, a Zürich based spin-off company from the ETH Zürich, developing non-invasive diagnostic tests for the accurate detection, prognosis and therapy selection of prostate cancer. This CHF 5 million financing round was led by Altos Venture, a Swiss venture capital firm chaired by Dr. Walter Fischli (co-founder of Actelion). All existing investors participated in this round, including Zürcher Kantonalbank and several private investors experienced in life science investments. The team at VISCHER was led by Matthias Staehelin (Partner) with Moritz Jäggy (Senior Associate), both Corporate.